In more detail, it explains heterogeneity in FGFR4 expression both across PAM50 subtypes and in cancer cell lines, but also within HER2E tumors irrespective of ERBB2 status, and may even be potentially informative as a biomarker for FGFR4 inhibitors. The gene discussed is ERBB2; the disease is cancer.